Finally, the evaluation of methylation in ctDNA via ddPCR, such as the detection of RASSF1A or paraoxonase 3 (PON3), may suggest the state of the disease and survival outcomes in CM patients, even in the absence of tumor mutation data for BRAF, RAS or EGFR genes [159,230]. The gene discussed is RASSF1; the disease is neoplasm.